Published in Clin Cancer Res on June 01, 2008
Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol (2012) 1.75
Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond) (2012) 1.54
Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci (2011) 1.22
Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides. Clin Exp Metastasis (2010) 1.09
Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. Int J Pharm (2010) 1.07
Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer (2009) 1.05
Biological rationale for the design of polymeric anti-cancer nanomedicines. J Drug Target (2012) 0.93
Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. ACS Nano (2014) 0.92
MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Sci Rep (2015) 0.91
Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. Clin Cancer Res (2012) 0.85
Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer. BMC Cancer (2013) 0.83
Targeted delivery of paclitaxel to tumor cells: synthesis and in vitro evaluation. J Med Chem (2010) 0.82
Hyaluronan as a therapeutic target in human diseases. Adv Drug Deliv Rev (2015) 0.81
The Extracellular Matrix in Epithelial Ovarian Cancer - A Piece of a Puzzle. Front Oncol (2015) 0.81
Glutathione-degradable drug-loaded nanogel effectively and securely suppresses hepatoma in mouse model. Int J Nanomedicine (2015) 0.79
Recent progress in the development of polysaccharide conjugates of docetaxel and paclitaxel. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.77
Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure. Int J Mol Sci (2012) 0.76
Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options. Clin Exp Metastasis (2016) 0.76
Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs. PLoS One (2014) 0.75
Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer. Oncoscience (2015) 0.75
Effects of anti-CD44 monoclonal antibody IM7 carried with chitosan polylactic acid-coated nano-particles on the treatment of ovarian cancer. Oncol Lett (2016) 0.75
The Aminosteroid Derivative RM-133 Shows In Vitro and In Vivo Antitumor Activity in Human Ovarian and Pancreatic Cancers. PLoS One (2015) 0.75
Drug-Loaded Polymeric Nanoparticles for Cancer Stem Cell Targeting. Front Pharmacol (2017) 0.75
Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol (2005) 9.27
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 6.03
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell (2011) 5.06
A MicroRNA targeting dicer for metastasis control. Cell (2010) 4.81
Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med (2015) 4.68
Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol (2010) 4.62
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev (2008) 4.36
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol (2003) 3.69
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 3.56
L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol (2003) 2.81
Vitamin K2 is a mitochondrial electron carrier that rescues pink1 deficiency. Science (2012) 2.65
Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother (2003) 2.65
IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol (2009) 2.64
The Atx1-Ccc2 complex is a metal-mediated protein-protein interaction. Nat Chem Biol (2006) 2.56
CASD-NMR: critical assessment of automated structure determination by NMR. Nat Methods (2009) 2.50
LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron (2012) 2.49
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A (2005) 2.49
SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature (2012) 2.46
Counting the zinc-proteins encoded in the human genome. J Proteome Res (2006) 2.38
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet (2011) 2.29
Effects of type 2 diabetes mellitus on coronary microvascular function and myocardial perfusion in patients without obstructive coronary artery disease. Eur J Nucl Med Mol Imaging (2012) 2.17
Zinc through the three domains of life. J Proteome Res (2006) 2.11
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
Identification of genes selectively regulated by IFNs in endothelial cells. J Immunol (2007) 1.87
Toll-like receptor 2 regulates intestinal inflammation by controlling integrity of the enteric nervous system. Gastroenterology (2013) 1.83
Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model. Circ Res (2008) 1.67
Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc Natl Acad Sci U S A (2003) 1.60
Common cancer biomarkers. Cancer Res (2006) 1.56
Metalloproteomes: a bioinformatic approach. Acc Chem Res (2009) 1.52
Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst (2006) 1.51
Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood (2011) 1.47
Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. J Clin Invest (2003) 1.47
Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. Int J Cancer (2005) 1.46
The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer. Nat Cell Biol (2009) 1.44
MGUard versus bAre-metal stents plus manual thRombectomy in ST-elevation myocarDial infarction pAtieNts-(GUARDIAN) trial: study design and rationale. Catheter Cardiovasc Interv (2012) 1.44
Operator's experience is the most efficient embolic protection device for carotid artery stenting. Circ Cardiovasc Interv (2013) 1.40
[Novel concepts in beta-adrenergic receptor signaling: therapeutic options for heart failure]. G Ital Cardiol (Rome) (2010) 1.40
Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial. High Blood Press Cardiovasc Prev (2015) 1.40
Solution structure and intermolecular interactions of the third metal-binding domain of ATP7A, the Menkes disease protein. J Biol Chem (2006) 1.40
Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics (2013) 1.39
Assembly of multiple CotC forms into the Bacillus subtilis spore coat. J Bacteriol (2004) 1.34
Role of arginine metabolism in immunity and immunopathology. Immunobiology (2007) 1.33
Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett (2008) 1.31
HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget (2013) 1.29
Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res (2008) 1.26
A hint to search for metalloproteins in gene banks. Bioinformatics (2004) 1.25
Occurrence of copper proteins through the three domains of life: a bioinformatic approach. J Proteome Res (2007) 1.24
MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res (2012) 1.22
Cytochrome c: occurrence and functions. Chem Rev (2006) 1.21
Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Blood (2009) 1.20
Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer. J Immunol (2008) 1.15
Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization. Cancer Res (2011) 1.14
A gene expression signature associated with survival in metastatic melanoma. J Transl Med (2006) 1.13
Solution structure of the apo and copper(I)-loaded human metallochaperone HAH1. Biochemistry (2004) 1.13
Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res (2008) 1.11
Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res (2009) 1.10
AKAP121 downregulation impairs protective cAMP signals, promotes mitochondrial dysfunction, and increases oxidative stress. Cardiovasc Res (2010) 1.09
Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proc Natl Acad Sci U S A (2006) 1.08
Antimicrobial activity of saponins from Medicago sp.: structure-activity relationship. Phytother Res (2006) 1.08
Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer (2006) 1.07
miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. Immunity (2013) 1.07
Mutations in the intellectual disability gene Ube2a cause neuronal dysfunction and impair parkin-dependent mitophagy. Mol Cell (2013) 1.06
The yeast complex I equivalent NADH dehydrogenase rescues pink1 mutants. PLoS Genet (2012) 1.06
Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol (2011) 1.06
Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors. J Immunol (2010) 1.05
Polarized monocyte response to cytokine stimulation. Genome Biol (2005) 1.04
Paramagnetically induced residual dipolar couplings for solution structure determination of lanthanide binding proteins. J Am Chem Soc (2002) 1.04
Inhibition of miR-92a increases endothelial proliferation and migration in vitro as well as reduces neointimal proliferation in vivo after vascular injury. Basic Res Cardiol (2012) 1.04
An NMR study of the interaction of the N-terminal cytoplasmic tail of the Wilson disease protein with copper(I)-HAH1. J Biol Chem (2009) 1.04
Melanoma-restricted genes. J Transl Med (2004) 1.03
IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine (2010) 1.02
RPF: a quality assessment tool for protein NMR structures. Nucleic Acids Res (2012) 1.02
Differential regulation of hypoxia-induced CXCR4 triggering during B-cell development and lymphomagenesis. Cancer Res (2007) 1.01
Predicting zinc binding at the proteome level. BMC Bioinformatics (2007) 1.01
Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase. J Immunol (2003) 1.01
An NMR study of the interaction between the human copper(I) chaperone and the second and fifth metal-binding domains of the Menkes protein. FEBS J (2005) 1.00
In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res (2009) 1.00
Genome-based analysis of heme biosynthesis and uptake in prokaryotic systems. J Proteome Res (2008) 1.00
Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg Oncol Clin N Am (2003) 1.00
A Grid-enabled web portal for NMR structure refinement with AMBER. Bioinformatics (2011) 0.99
The functions of Sco proteins from genome-based analysis. J Proteome Res (2007) 0.99
Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res (2008) 0.99
The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res (2003) 0.99
Suppression of tumor growth and cell proliferation by p13II, a mitochondrial protein of human T cell leukemia virus type 1. Proc Natl Acad Sci U S A (2004) 0.99
Solution structure and characterization of the heme chaperone CcmE. Biochemistry (2002) 0.98
Rat carotid artery dilation by PTCA balloon catheter induces neointima formation in presence of IEL rupture. Am J Physiol Heart Circ Physiol (2002) 0.98
The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica (2010) 0.98